IOWA | Health and Human Services

Iowa Medicaid Drug Utilization Review (DUR) Commission

February 5, 2025

Time: 9:30 a.m. – 1:30 p.m. CT
Location: Virtual Only
Teams Link: https://teams.microsoft.com/l/meetup-join/19%3ameeting_NDI2MzA0NTktODdjNC00NDZmLTljZmEtOTQ5ODZiZjAxMTcx%40thread.v2/0?context=%7b%22Tid%22%3a%228d2c7b4d-085a-4617-8536-38a76d19b0da%22%2c%22Oid%22%3a%22982a0572-2333-4ea7-b2e0-b02af2367c61%22%7d

Final Agenda

1. Welcome & Introductions
    a) Commission Members and Staff
2. Commission Business
    a) Approval of the November 6, 2024 Meeting Minutes
    b) November 2024 DUR Recommendation Letter to DHHS
    c) P&T November 2024 Recommendation to DUR Commission
    d) Follow-Up from Previous Meeting(s)
3. Iowa Medicaid Pharmacy Update
4. Prevalence Report Summaries
    a) Molina Healthcare of Iowa
    b) Wellpoint Iowa
    c) Fee-for-Service
    d) Iowa Total Care
    e) Comparative Summary
5. Public Comment* (See attached Conflict of Interest Disclosure)
    - Verbal - Must **pre-register** to provide verbal public comment and submit a completed conflict of interest disclosure. *For hybrid meetings, verbal public comment will be allowed in person and virtually*.
    - Written – Must submit written comments and a completed conflict of interest disclosure.
    - **All submissions must be received no later than 4:30 p.m. CST January 29, 2025.**
    - **Email to pba_iadur@optum.com.**
6. Retrospective DUR
    a) Data Presentation(s)
        i. Stimulant Medication Utilization without Supporting Diagnosis – Follow Up
        ii. 72-Hour Emergency Override Utilization Review
        iii. Concurrent use of GLP-1 Receptor Agonist and DPP-4 Inhibitor
    b) Proposal(s)
        i. Evaluation of Dornase Alpha in Cystic Fibrosis Patients on Modulator Therapy
        ii. LABA+ICS in COPD
    c) Commission Recommendations for Retrospective DUR Agenda Topics
7. Break (10 minutes)
8. Prior Authorization
    a) Aprocitentan (Tryvio) – Initial Review
    b) CNS Stimulants and Atomoxetine – Initial Review

c) Direct Oral Anticoagulants – Initial Review
d) Letermovir (Prevymis) – Initial Review
e) Peanut (*Arachis hypogaea*) Allergen Powder-DNFP (Palforzia) – Initial Review
f) Oxybate Products – Initial Review
g) Tirzepatide (Zepbound) for OSA – Initial Review
h) Dupilumab (Dupixent) – Second Review
i) Ensifentrine (Ohtuvayre) – Second Review
j) Incretin Mimetics for Non-Diabetes Indications – Second Review
k) Select Preventative Migraine Treatments – Second Review
l) Topical Roflumilast (Zoryve) – Second Review
m) Vonoprazan (Voquezna) – Second Review

9. Miscellaneous
   a) DUR Digest Vol. 37, No. 1 – Second Review
10. MedWatch

FDA Proposes Ending Use of Oral Phenylephrine as OTC Monograph Nasal Decongestant Active Ingredient After Extensive Review

FDA approves REMS modification, advancing new drug disposal option

FDA approves new treatment for uncomplicated urinary tract infections in adult women who have limited or no alternative oral antibiotic treatment options

FDA Approves New Treatment for Hemophilia A or B

FDA approves drug for heart disorder caused by transthyretin-mediated amyloidosis

Ocaliva (obeticholic acid) by Intercept Pharmaceuticals: Drug Safety Communication - Serious Liver Injury Being Observed in Patients without Cirrhosis

FDA Adds Warning About Rare Occurrence of Serious Liver Injury with Use of Veozah (fezolinetant) for Hot Flashes Due to Menopause. Stop Medicine if Signs and Symptoms of Liver Injury Occur - Drug Safety Communication

FDA Recommends Changes to Labeling for Transmucosal Buprenorphine Products Indicated to Treat Opioid Use Disorder

11. Adjournment

*Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted once during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on. Any individual speaking, presenting, or providing written comment must register and complete a conflict-of-interest disclosure. Registration and completed forms must be provided to DUR staff at least one week prior to the scheduled meeting at pba_iadur@optum.com. Failure to register and submit a complete conflict-of-interest disclosure form by the specified date and time will result in a delay of your comments being considered until the next scheduled meeting.

www.iadur.org

For more information, contact the DUR Project Coordinator, Pamela Smith, R.Ph., at pba_iadur@optum.com or (515) 974-3131.

Next Meeting
May 7, 2025
Meeting Format: TBD